Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5581717 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 7 Pages |
Abstract
Treatment of patients with acute promyelocytic leukemia has significantly improved with the introduction of target specific agents all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) with long term survival a reality for the majority of patients. This can serve as a paradigm for cancer therapy where with the introduction of more potent target-specific drugs our reliance on the traditional cytotoxic agents is likely to diminish and less toxic and more effective regimens are likely to replace the current intensive chemotherapy regimens.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Farhad Ravandi, Richard Stone,